- Home
- URGN vs WGO Comparison
URGN vs WGO Comparison
Compare URGN & WGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- WGO
- Stock Information
- Founded
- URGN 2004
- WGO 1958
- Country
- URGN United States
- WGO United States
- Employees
- URGN N/A
- WGO N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- WGO Homebuilding
- Sector
- URGN Health Care
- WGO Industrials
- Exchange
- URGN Nasdaq
- WGO Nasdaq
- Market Cap
- URGN 830.4M
- WGO 893.6M
- IPO Year
- URGN 2017
- WGO N/A
- Fundamental
- Price
- URGN $16.82
- WGO $29.88
- Analyst Decision
- URGN Strong Buy
- WGO Buy
- Analyst Count
- URGN 8
- WGO 12
- Target Price
- URGN $28.50
- WGO $39.36
- AVG Volume (30 Days)
- URGN 1.2M
- WGO 483.7K
- Earning Date
- URGN 11-05-2025
- WGO 10-22-2025
- Dividend Yield
- URGN N/A
- WGO 4.69%
- EPS Growth
- URGN N/A
- WGO N/A
- EPS
- URGN N/A
- WGO N/A
- Revenue
- URGN $94,238,000.00
- WGO $2,741,800,000.00
- Revenue This Year
- URGN $39.63
- WGO N/A
- Revenue Next Year
- URGN $111.49
- WGO $5.80
- P/E Ratio
- URGN N/A
- WGO N/A
- Revenue Growth
- URGN 10.85
- WGO N/A
- 52 Week Low
- URGN $3.42
- WGO $28.00
- 52 Week High
- URGN $21.71
- WGO $65.65
- Technical
- Relative Strength Index (RSI)
- URGN 42.97
- WGO 33.19
- Support Level
- URGN $15.86
- WGO $29.66
- Resistance Level
- URGN $17.43
- WGO $35.10
- Average True Range (ATR)
- URGN 1.06
- WGO 1.14
- MACD
- URGN -0.15
- WGO -0.44
- Stochastic Oscillator
- URGN 23.05
- WGO 4.04
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About WGO Winnebago Industries Inc.
Winnebago Industries manufactures Class A, B, and C motor homes along with towables, customized specialty vehicles, boats, and parts. Headquartered in Eden Prairie, Minnesota, Winnebago has been producing recreational vehicles since 1958. Revenue was nearly $3 billion in fiscal 2024. Winnebago expanded into towables in 2011 with the acquisition of SunnyBrook and acquired Grand Design in November 2016. Towables made up 83% of the firm's RV unit volume, up from 31% in fiscal 2016. The company's total RV unit volume was 38,796 in fiscal 2024. Winnebago expanded into boating in 2018 with the purchase of Chris-Craft, bought premium motor home maker Newmar in November 2019, and bought Barletta pontoon boats in August 2021. It also is developing electric and autonomous technology.